Search

The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐free survival was improved in the ASCT‐NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT‐NMA alloSCT can be considered as upfront therapy in HR‐MM. [ABSTRACT FROM AUTHOR]

A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML) Among these 9 patients, 4 patients had AML, of which 3 received a 2nd transplant and 1 patient only received intensive chemotherapy; the remaining 5 patients either had chronic myeloid or lymphocytic leukemia or MDS. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. [Extracted from the article]

Discusses the development of bone marrow transplantation as a possible treatment for leukemia. Demands placed by the procedure upon nursing staff; Characteristics of transplant candidates; Infusion procedure; Precautions designed to counteract the toxic effects of the chemotherapeutic agent Cytoxan.